Nivolumab plus ipilimumab was effective against metastatic renal cell carcinoma in a hemodialysis patient with end-stage renal disease

Ogata Ayato, Hayashida Michikata, Sakamoto Noboru, Tsukuda Fumio, Horiguchi Yutaka, Koga Shoji

doi:10.4009/jsdt.53.547

Bibliographic Information

Other Title

転移性腎細胞癌に対してニボルマブ・イピリムマブ併用療法が著効した血液透析患者の1例
症例報告転移性腎細胞癌に対してニボルマブ・イピリムマブ併用療法が著効した血液透析患者の1例
ショウレイホウコクテンイセイジンサイボウガンニタイシテニボルマブ・イピリムマブヘイヨウリョウホウガチョコウシタケツエキトウセキカンジャノ 1レイ

Search this article

Description

<p>The patient was a 69-year-old male. He had been on hemodialysis due to end-stage renal disease caused by diabetic nephropathy for 4 months. He had undergone coronary artery bypass graft surgery 7 years ago. A CT scan performed as part of a routine cardiovascular check-up incidentally revealed a left renal tumor and multiple pulmonary metastases. He was referred to our department. The clinical diagnosis was metastatic renal cell carcinoma (cT1bN0M1, intermediate risk according to the IMDC classification), and immune checkpoint inhibitor combination therapy, involving nivolumab plus ipilimumab, was started. A full therapeutic dose was administered. After 2 courses (6 weeks later), the left renal tumor and pulmonary metastases had decreased in size (a partial response). After 8 courses (18 weeks later), the sizes of the tumors had decreased further. The patient only experienced one adverse effect; i.e., grade 2 hypothyroidism was observed at the end of the 4th course (12 weeks later); however, it was quickly resolved using oral medication. We consider that nivolumab plus ipilimumab combination therapy is acceptable and effective against metastatic renal cell carcinoma in hemodialysis patients with end-stage renal disease.</p>

Journal

Nihon Toseki Igakkai Zasshi

Nihon Toseki Igakkai Zasshi 53 (11), 547-551, 2020

The Japanese Society for Dialysis Therapy

Keywords

Details 詳細情報について

Export

Report a problem